Midazolam as an Intravenous Induction Agent for General Anaesthesia: A Clinical Trial

Abstract

The peripheral and central nervous, cardiovascular and respiratory effects of midazolam 0.15 mglkg, administered intravenously, were studied in 57 patients. Midazolam induced anaesthesia satisfactorily in 78% of the patients, the remainder required either further doses of midazolam, or alternative induction agents. There was no pain on injection. No evidence of thrombophlebitis was apparent up to 72 hours after injection. Mean systolic arterial pressure decreased from 128 mm Hg to 114 mm Hg and mean diastolic pressure decreased from 75 mm Hg to 67 mm Hg (P < 0.005) four minutes after injection. Mean heart rate increased from 81 beatslmin to 88 beatslmin (P < 0.005) one minute after injection. Apnoea occurred in 14 patients, with a mean onset time of 82 sec and a mean duration of 30 sec. Patients showed a decrease in mean respiratory rate from 13.7 breathslmin to 12.8 breathslmin two minutes after injection of midazolam. A larger dose than used in this study would be necessary for satisfactory use of midazolam as an induction agent for general anaesthesia.

Evaluation of Midazolam as an Intravenous Induction Agent for General Anaesthesia-Comparision with Thiopentone

“…Patients showed a decrease in mean respiratory rate from 13.7 breaths/min to 12.8 breaths/ min two minutes after injection of midazolam. 20 When midazolam is administered intravenously for induction of general anaesthesia, respiratory depression occurs through a marked decrease in the ventilatory response to carbon dioxide. 21 Our study showed the lower post-operative incidence of nausea and vomiting was observed in midazolam compared to thiopentone with incidence thrombophlebitis was found more in thiopentone groups Study conducted by Abraham, J et al 15 , found postoperative nausea, vomiting and thrombophlebitis were significantly low with midazolam.…”

A Comparison of Midazolam and Diazepam for Induction of Anaesthesia in High-Risk Patients

“…2 -5 Recently, midazolam, a watersoluble imidazo-benzodiazepine with a relatively short half-life, 6 has been introduced in clinical anaesthesia practice. With midazolam's short half-life, the length of postoperative somnolence is reduced 7 and its water solubility attenuates venous irritation at the injection site 8 and produces a relatively rapid induction time. 9 The purpose of our study was to compare the ·M.D., Associate Professor.…”